UB develops a more sustainable method for manufacturing peptides for biomedical and industrial applications
A research team from the University of Barcelona has developed a new methodology for peptide synthesis that offers a safer, more sustainable and more efficient alternative to the use of trifluoroacetic acid (TFA), a reagent widely used in this type of chemical process.
The technology has been developed by the group led by Dr Francesc Rabanal, from the Department of Inorganic and Organic Chemistry at the Faculty of Chemistry of UB. The team has extensive experience in the research and development of peptide-based chemical entities, a field with important applications in the biomedical, pharmaceutical, cosmetic and biotechnological sectors.
Peptides are molecules composed of short chains of amino acids that play a key role in the development of new drugs, cosmetic products, diagnostic tools and other high-value-added applications. In conventional peptide synthesis processes, TFA is often used in the final stage, although this reagent is increasingly under regulatory scrutiny due to its environmental impact and its association with persistent fluorinated substances.
The new methodology developed by UB replaces TFA with an alternative fluorine-free acid that reduces the environmental impact of the process and improves operational safety. In addition, the system is compatible with standard peptide synthesis workflows, both in solid-phase and liquid-phase synthesis, allowing it to be integrated into existing manufacturing processes without requiring major structural modifications.
Tests carried out by the research team have demonstrated high efficiency in terms of yield and purity, even in complex peptides. According to the results obtained, the method can achieve yields of up to 97% and purities of up to 99%, is approximately 20% more cost-effective than TFA, and offers a safer profile as it is non-volatile and reduces associated exposure risks.
“This technology responds to a growing industry need for alternatives to TFA that are more sustainable and safer, while maintaining synthesis efficiency. Our method enables progress towards a more environmentally friendly peptide production process that is compatible with current manufacturing standards and aligned with upcoming European regulations,” highlights Dr Francesc Rabanal.
The technology is currently protected through a European patent application filed in May 2026. The Bosch i Gimpera Foundation, the University of Barcelona’s knowledge transfer office, is seeking a licensing agreement to integrate this methodology into peptide manufacturing processes, although other forms of collaboration with interested companies may also be considered.